Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Conditions:   Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8;   Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Human Papillomavirus Positive;   Oropharyngeal Squamous Cell Carcinoma;   p16 Positive Neoplastic Cells Present;   Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions:   Biological: Durvalumab;   Procedure: Modified Radical Neck Dissection;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Stereotactic Body Radiation Therapy;   Procedure: Transoral Robotic Surgery;   Biological: Tremelimumab
Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
Not yet recruiting

https://ift.tt/2LZmKBg